Cholangiocarcinoma: A clinical case of long-lasting response to immunochemotherapy

Cholangiocellular carcinoma is a heterogeneous group of malignant neoplasms of the biliary tract. It accounts for approximately 3% of all gastrointestinal tumors and is the second most common primary liver tumor after hepatocellular carcinoma. Surgery is the only cure. Surgical treatments are among the most complex in hepatopancreatobiliary surgery. Standard first-line therapy with gemcitabine-based chemotherapy has demonstrated a modest improvement in survival in patients with advanced cholangiocellular carcinoma. Despite its role as the cornerstone of first-line therapy, chemotherapy produces suboptimal response rates, and overall survival highlights the urgent need for improved therapeutic strategies. The TOPAZ-1 trial, which included an immuno-oncology agent, demonstrated an improvement in overall survival. In the case described above, the patient first presented for this condition in 2022. After diagnosis verification, chemoembolization and surgical treatment were performed. Disease progression began in 2023. Based on the progression, chemotherapy in combination with durvalumab was initiated. In the case of local progression, a course of stereotactic radiotherapy was administered. This clinical case demonstrates the results of combining systemic therapy and local control methods. Progression-free survival with durvalumab therapy was 26 months. Thus, this option demonstrated the potential of modern immunochemotherapy and stereotactic radiotherapy.

1. Zamotina AG, Falaleeva NA, Kucherov VV, Petrov LO, Petrosyan AP, Vovchenko AA. Cholangiocarcinoma. Epidemiology, classification, diagnosis, treatment methods (literature review). Clinical Review for General Practice. 2024;5(7):12–16. (In Russ.) https://doi.org/10.47407/kr2024.5.7.00443.

2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. https://doi.org/10.3322/caac.21820.

3. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463–473. https://doi.org/10.1097/00000658-199610000-00005.

4. Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588. https://doi.org/10.1038/s41575-020-0310-z.

5. Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7(1):65. https://doi.org/10.1038/s41572-021-00300-2.

6. Ilyas SI, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–1229. https://doi.org/10.1053/j.gastro.2013.10.013.

7. Mizuno T, Ebata T, Nagino M. Advanced hilar cholangiocarcinoma: An aggressive surgical approach for the treatment of advanced hilar cholangiocarcinoma: Perioperative management, extended procedures, and multidisciplinary approaches. Surg Oncol. 2020;33:201–206. https://doi.org/10.1016/j.suronc.2019.07.002.

8. Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol. 2020;26(25):3542–3561. https://doi.org/10.3748/wjg.v26.i25.3542.

9. Istanbouli A, Patel S, Almerey T, Li Z, Stauffer JA. Surgical Treatment for Intrahepatic, Peri-Hilar, and Distal Cholangiocarcinoma: 20-Single Institutional Year Experience. Am Surg. 2023;89(4):621–631. https://doi.org/10.1177/00031348211034751.

10. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18(3):651–658. https://doi.org/10.1245/s10434-010-1325-4.

11. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–762. https://doi.org/10.1097/01.sla.0000251366.62632.d3.

12. Ruff SM, Cloyd JM, Pawlik TM. Annals of Surgical Oncology Practice Guidelines Series: management of primary liver and biliary tract cancers. Ann Surg Oncol. 2023;30(13):7935–7949. https://doi.org/10.1245/s10434-023-14255-z.

13. Brandi G, Rizzo A. IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience? Int J Mol Sci. 2022;23(18):10869. https://doi.org/10.3390/ijms231810869.

14. Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun. 2021;27:100354. https://doi.org/10.1016/j.ctarc.2021.100354.

15. Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM et al. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses. Hepatology. 2021;74(4):1914–1931. https://doi.org/10.1002/hep.31862.

16. Macarulla T, Ren Z, Chon HJ, Park JO, Kim JW, Pressiani T et al. Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial. J Clin Oncol. 2025;43(5):545–557. https://doi.org/10.1200/JCO.24.00337.

17. Qin S, Liang T, Gu S, Gou H, Peng C, Pan Y et al. 47P First-line pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study. Ann Oncol. 2024;35(2):S230. https://doi.org/10.1016/j.annonc.2024.08.056.

18. Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694–704. https://doi.org/10.1016/S2468-1253(24)00095-5.

19. Burris HA 3rd, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25(5):626–635. https://doi.org/10.1016/S1470-2045(24)00082-2.

20. Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https://doi.org/10.1056/EVIDoa2200015.

21. Kawasaki S, Imamura H, Kobayashi A, Terumasa N, Miwa S, Miyagawa S. Results of Surgical Resection for Patients With Hilar Bile Duct Cancer. Ann Surg. 2003;238(1):84–92. https://doi.org/10.1097/01.SLA.0000074984.83031.02.

22. Herber S, Otto G, Schneider J, Manzl N, Kummer I, Kanzler S et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2007;30(6):1156–1165. https://doi.org/10.1007/s00270-007-9032-7.

23. Liu P, Ye H, Song L, Li H, Fu M, Dong Z. Outcomes of stereotactic body radiotherapy for unresectable cholangiocarcinoma: a meta-analysis and systematic review. PeerJ. 2025;13:e19909. https://doi.org/10.7717/peerj.19909.